Should You Buy the Dip in This Oversold Michael Burry Stock?

Core Viewpoint - Molina Healthcare's shares plummeted over 25% following disappointing guidance for fiscal 2026, with earnings projected at $5 per share, significantly lower than the previous estimate of approximately $14 [1]. Group 1: Stock Performance - Year-to-date, Molina Healthcare's stock has declined nearly 35% from its high [2]. - The stock is currently trading below its major moving averages, indicating a broader downward trend [7]. Group 2: Financial Guidance and Market Reaction - The company anticipates an elevated medical cost ratio for the year, contributing to the lowered earnings guidance [1]. - Despite the sharp decline, investor Michael Burry remains optimistic about his investment in Molina, comparing it to Berkshire Hathaway's investment in Geico [4]. Group 3: Investment Considerations - Molina Healthcare is currently trading at a discount to its intrinsic value, but faces increased pressure from proposed reductions in Medicare Advantage reimbursement rates, making it a high-risk investment [5]. - Unlike competitors such as UnitedHealth and Humana, Molina does not pay a dividend, making it less attractive for income-focused investors [5]. - Options traders express skepticism about the stock's recovery, with predictions indicating a potential further decline of 20% over the next five months [7]. Group 4: Analyst Perspectives - Wall Street analysts suggest that the recent selloff in Molina shares may have been excessive, indicating potential for recovery despite the associated risks [9].